News Breaks |
|
|
| October 16, 2012 |
| 06:48 EDT |  | LLY, ABT | Stocks with implied volatility movement; LLY ABT
Stocks with implied volatility movement; Eli Lilly (LLY), Abbott (ABT) according to iVolatility. |
|
|
News For LLY;ABT From The Last 14 Days Check below for free stories on LLY;ABT the last two weeks. |
|
|
| May 20, 2013 |
| 10:11 EDT |  | ABT | On The Fly: Analyst Upgrade Summary
 Subscribe for More Information |
|
| 06:01 EDT | | ABT | Abbott upgraded to Buy from Neutral at Goldman
Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38. |
|
| May 16, 2013 |
| 08:55 EDT |  | LLY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| May 14, 2013 |
| 09:09 EDT |  | LLY | Eli Lilly announces CEO John Lechleiter recovering from surgery
Subscribe for More Information |
|
| 07:24 EDT | | LLY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 10, 2013 |
| 11:48 EDT |  | LLY | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information |
|
| 08:02 EDT | | LLY | Eli Lilly's Enzastaurin Phase III study did not meet primary endpoint
Eli Lilly announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma. The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies. Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30M. The company's previously-issued financial guidance for 2013 remains unchanged. |
|
| May 9, 2013 |
| 11:01 EDT | | LLY | Sears Holdings names Jeff Balagna Chief Information Officer
Subscribe for More Information |
|
| 07:04 EDT | | ABT | Abbott announces CE Mark for A1c test
Subscribe for More Information |
|
| May 6, 2013 |
| 18:42 EDT | | LLY | Eli Lilly and Boehringer announce results from Phase 3 study of linagliptin
Subscribe for More Information |
| |
| 16:40 EDT | | LLY | Eli Lilly announces CEO Dr. John Lechleiter to undergo surgery
Subscribe for More Information |
|
| 12:35 EDT | | ABT | Abbott management to meet with Jefferies
Subscribe for More Information |
|
| 07:34 EDT | | ABT | Conference Forum to host a summit
Subscribe for More Information |
|
| 07:18 EDT | | ABT | American Congress of Obstetrics and Gynecology to hold annual meeting
Subscribe for More Information |
|
|
|
|
|
